FP 008 - Fapon Biopharma
Alternative Names: FP-008 - Fapon BiopharmaLatest Information Update: 05 Jun 2025
At a glance
- Originator Fapon Biopharma
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 10 replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 May 2025 Fapon Biopharma plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV, Injection), in August 2025 (NCT06990698)
- 25 Apr 2025 Pharmacodynamics data from preclinical trial presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Feb 2025 US FDA approves IND application for FP 008 in Solid tumour